Erdafitinib
This page contains brief information about erdafitinib and a collection of links to more information about the use of this drug, research results, and ongoing clinical trials.
FDA label information for this drug is available at DailyMed.
Use in Cancer
Erdafitinib is approved to treat:
- Urothelial carcinoma (a type of bladder cancer) that is locally advanced or has metastasized (spread to other parts of the body) and has certain mutations in the FGFR3 gene or a fusion gene involving the FGFR3 or FGFR2 gene. It is used in adults whose disease got worse during or after treatment with at least one type of platinum chemotherapy.
This use is approved under FDA’s Accelerated Approval Program. As a condition of approval, a confirmatory trial(s) must show that erdafitinib provides a clinical benefit in these patients.
Erdafitinib is also being studied in the treatment of other types of cancer.
More About Erdafitinib
Definition from the NCI Drug Dictionary - Detailed scientific definition and other names for this drug.
Research Results and Related Resources
Targeted Drug Erdafitinib Benefits Some Patients with Advanced Bladder Cancer
Clinical Trials Accepting Patients
Find Clinical Trials for Erdafitinib - Check for trials from NCI's list of cancer clinical trials now accepting patients.